Diagnostic and prognostic role of TFF3, Romo‑1, NF‑κB and SFRP4 as biomarkers for endometrial and ovarian cancers: a prospective observational translational study

Hasan Turan1 · Salvatore Giovanni Vitale2 · Ilker Kahramanoglu3 · Luigi Della Corte4 · Pierluigi Giampaolino5 · Asli Azemi6 · Sinem Durmus6 · Veyssel Sal7 · Nedim Tokgozoglu5 · Tugen Bese9 · Macit Arvas10 · Fuat Demirkiran9 · Remise Gellisgen6 · Sennur Ilvan11 · Hafize Uzun6

Received: 2 March 2022 / Accepted: 1 April 2022 / Published online: 24 April 2022
© The Author(s) 2022

Abstract

Purpose This study aimed to evaluate trefoil factor 3 (TFF3), secreted frizzled‑related protein 4 (sFRP4), reactive oxygen species modulator 1 (Romo1) and nuclear factor kappa B (NF‑κB) as diagnostic and prognostic markers of endometrial cancer (EC) and ovarian cancer (OC).

Methods Thirty‑one patients with EC and 30 patients with OC undergone surgical treatment were enrolled together with 30 healthy controls in a prospective study. Commercial ELISA kits determined serum TFF‑3, Romo‑1, NF‑κB and sFRP‑4 concentrations.

Results Serum TFF‑3, Romo‑1 and NF‑κB levels were significantly higher in patients with EC and OC than those without cancer. Regarding EC, none of the serum biomarkers differs significantly between endometrial and non‑endometrioid endometrial carcinomas. Mean serum TFF‑3 and NF‑κB levels were significantly higher in advanced stages. Increased serum levels of TFF‑3 and NF‑κB were found in those with a higher grade of the disease. Regarding OC, none of the serum biomarkers differed significantly among histological subtypes. Significantly increased serum levels of NF‑κB were observed in patients with advanced‑stage OC than those with stage I and II diseases. No difference in serum biomarker levels was found between those who had a recurrence and those who had not. The sensibility and specificity of these four biomarkers in discriminating EC and OC from the control group showed encouraging values, although no one reached 70%.

Conclusions TFF‑3, Romo‑1, NF‑κB and SFRP4 could represent new diagnostic and prognostic markers for OC and EC. Further studies are needed to validate our results.

Keywords Biomarkers · Endometrial cancer · Ovarian cancer · TFF‑3 · Romo‑1 · NF‑κB · SFRP4

Introduction

Ovarian cancer (OC) is the most lethal female reproductive tract malignancy worldwide, as reported by the National Cancer Institute (NCI), which estimates the death of 140,000 women every year [1]. Endometrial cancer (EC) is less lethal, since about 80% of cases are diagnosed in the early stages (I–II according to the International Federation of Gynecology and Obstetrics—FIGO) [2]. However, EC has the primacy of the most common gynaecological malignant disease, with an incidence rising alongside the growing prevalence of obesity. In 2018 over 380,000 new cases of EC and 295,000 new cases of OC have been registered with 89,000 and 184,000 deaths, respectively [3, 4].

Serum biomarkers can be used for screening, diagnosis, prognosis, or treatment monitoring of EC and OC, playing a fundamental role in primary and secondary prevention. Two different institutions have provided the definition of biomarkers: the NCI, which defines biomarkers as ‘a biological molecule found in blood, other bodily fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease’ [5], and the World Health Organization (WHO), which defines them as ‘any
substance, structure or process that can be measured in the body or its products and influence or predict the incidence of outcome or disease’ [6]. Recent discoveries of genetic pathways and tumor biomarkers in different types of cancers have opened new advances for using some of these biomarkers for the diagnosis, prognosis and as targets for emerging therapies. The oncosuppressor genes BRCA1 and 2 are the best-known genes involved in hereditary OC and breast cancer: indeed, they account for 70–80% of hereditary OC cases [7, 8]. Nowadays, numerous markers are already employed for the diagnosis and prognosis of OC. In addition, many others are being evaluated to predict progression as early as possible and thus find strategies to detect and prevent a recurrence [9].

CA125, human epididymis protein 4 (HE4), apolipoprotein A1, transthyretin, transferrin, and β2-macroglobulin are validated biomarkers used in the contest of Risk of Malignancy Index (RMI), Risk of Malignancy Algorithm (ROMA), OVA1 algorithms and International Ovarian Tumor Analysis (IOTA). These algorithms are used to distinguish benign diseases from malignant ones [10]. However, no biomarkers are currently used in daily medical practice for EC, though CA125 and HE4 can help prognosis and survival [11].

In this study, we evaluated the role of four proteins as biomarkers, still poorly investigated for OC and EC but which have aroused great interest in the context of other tumor diseases: trefoil factor 3 (TFF3), nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB), secreted frizzled-related protein 4 (sFRP4), and Reactive Oxygen Species Modulator 1 (Romo-1).

TFF3 is an estrogen-regulated oncogene, member of the trefoil factor family that includes small proteins secreted and expressed by mucus secretory epithelia mainly in the gastrointestinal tract [12]. TFF-3 has been reported to be overexpressed both as a gene and as a protein in human neoplasms, including intestinal, pancreatic, and prostate cancers [13, 14] and be involved in gastric cancer progression [15]. Moreover, in breast cancer, the TFF-3 gene is regulated consistently by estrogen, and similar relations were also found in EC [16, 17].

NF-κB, a transcriptional factor involved in regulating the immune response and inflammation, is constitutively activated in several cancers, such as breast, colorectal, head and neck carcinomas. Growing evidence supports a significant role in oncogenesis due to the regulation of this transcriptional factor on the expression of genes involved in different processes, such as proliferation, migration, and apoptosis, related to cancer development and progression [18]. Furthermore, NF-κB may be responsible for reducing the efficacy of chemotherapy, inducing the expression of the multidrug resistance P-glycoprotein [18].

sFRP4 is part of a family of five secreted glycoproteins involved as modulators of Wnt signalling. Decreased expression or silencing of SFRP4 resulting in Wnt-pathway overactivation leading to inhibition of tumor cell apoptosis seems common in most, if not all, human cancers [19].

Romo-1 is upregulated in several cancers type. It is one of the most important proteins in the inner membrane of mitochondria involved in the production of Reactive Oxygen Species (ROS) by complex III of the mitochondrial electron transport chain. Romo-1 has been found in various neoplasm cells, responsible for the invasion and progression of cancer cells. Finally, Romo-1 seems to be associated with planned cell death (apoptotic pathways). Indeed, the increased expression of intracellular ROS promotes the release of cytochrome C of the mitochondria and triggers the caspas, resulting in cell death [20].

The purpose of our research was to investigate these molecules as diagnostic and prognostic biomarkers in preoperative samples of women with EC and OC to find their possible role in the management of these two cancers.

**Materials and methods**

This prospective observational study was carried out at Cerrahpasa Faculty of Medicine, Division of Gynecologic Oncology, between April 2017 and May 2019. The study was approved by the Ethics Committee of Istanbul University-Cerrahpasa, School of Medicine (registration number: 83045809–604.01.02). In addition, written informed consent was obtained from all patients. The study was evaluated, selected and funded [funding number: TAB-2017–22506] by Istanbul University-Cerrahpasa, School of Medicine, Turkey, after rigorous peer-review.

The manuscript was prepared following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement [21].

Preoperative serum samples were obtained from a nonconsecutive series of EC and OC patients. Exclusion criteria were defined as the presence of one or more of the following: (I) metastatic EC or OC; (II) patients who were operated in another clinic; (III) neoadjuvant chemotherapy or radiotherapy; (IV) secondary malignancy.

The same two gynaecological pathologists made all histopathological diagnoses: in case of disagreement, a further evaluation was required by a third pathologist. The histological type and stage of the disease followed FIGO classification [22, 23]. The charts and pathological findings were reviewed without knowing the preoperative TFF-3, Romo-1, NF-κB and SFRP4 values.

Among OC patients, maximal cytoreduction was defined as removing all gross tumor tissue with no visible disease. Optimal cytoreduction was defined as a residual volume...
of 1 cm or more minor after surgery. Residual tumor more than 1 cm was classified as suboptimal cytoreduction. Blood samples were collected in EDTA-containing tubes and anti-coagulant-free tubes after an overnight fast. Plasma and serum were separated immediately and stored at -80°C until analysis. After reaching the desired number of cases in both groups, all serum samples were melted at room temperature at the Medical Biochemistry Laboratory of Istanbul University-Cerrahpasa. Serum TFF3, Romo-1, NF-κB and SFRP4 concentrations were determined by commercial ELISA kits (Elabscience, USA), based on sandwich principle, according to the manufacturer’s instructions.

**Statistical analysis**

Statistical analyses were performed using SPSS version 21. Patients’ characteristics and clinical features were summarized using standard descriptive statistics. Mann–Whitney U test was used for comparison between two groups. T test was used in the comparison of independent samples’ average. Receiver operating characteristics curves (ROC) were created for TFF3, Romo-1, NF-κB and SFRP4 serum concentrations as diagnostics for EC and OC by plotting sensitivity vs 1-specificity and area under the curve (AUC) was calculated for both markers. All p values were two-sided, and p<0.05 were considered statistically significant.

**Results**

A total of 101 patients were included in the study. The control group consisted of 30 women. There were 31 and 40 patients in EC and OC cancer groups, respectively.

Age, BMI and menopausal status were similar between control, EC and OC groups (Table 1).

Serum TFF-3, Romo-1 and NF-κB levels were significantly higher in patients with EC/OC compared to control (TFF3: 3.699 ± 0.194 (mean ± SD) and 3.672 ± 0.228 in EC (respectively) vs (vs) 3.286 ± 0.253 ng/mL in control group, p = 0.01; Romo1 2.5 ± 0.2 and 2.6 ± 0.2 in OC and EC (respectively) vs 1.7 ± 0.2 ng/mL in control group, p = 0.01; NF-κB 3.2 ± 0.4 and 3.2 ± 0.5 in OC and EC vs 2.1 ± 0.3 ng/mL in control group, p < 0.01).

Serum SFRP4 levels were significantly lower in cancer groups compared to the control group (2.1 ± 0.3 and 2.2 ± 0.4 in OC and EC (respectively) vs 2.9 ± 0.5 in the control group, p = 0.05). For more details, see Table 1.

As illustrated in Fig. 1, sensitivity and specificity of TFF3 for discriminating EC from the control group were 64.5% and 63.3%, respectively, when a cutoff serum TFF3 level of 3.559 ng/mL was applied. The same sensitivity and specificity values were found for Romo1 with a cutoff serum level of 1.9 ng/mL.

**Table 1** Comparison of clinical characteristics and level of serum markers between control and cancer groups

|                      | Control group (n=30) | Endometrial cancer (n=31) | Ovarian cancer (n=40) | p     |
|----------------------|----------------------|---------------------------|-----------------------|-------|
| Age, years           | 50.1 ± 12.3          | 54.1 ± 8.7                | 56.6 ± 11.9           | NS    |
| BMI, kg/m²           | 28.2 ± 4.1           | 31.0 ± 3.3                | 26.9 ± 3.6            | NS    |
| Postmenopausal       | 21 (70)              | 24 (77.4)                 | 30 (75)               | NS    |
| TFF3, pg/mL          | 3.286 ± 0.253        | 3.672 ± 0.228             | 3.699 ± 0.194         | 0.01  |
| Romo1, ng/mL         | 1.7 ± 0.2            | 2.6 ± 0.2                 | 2.5 ± 0.2             | 0.01  |
| NF-κB, ng/mL         | 2.1 ± 0.3            | 3.2 ± 0.5                 | 3.2 ± 0.4             | <0.01 |
| SFRP4, ng/mL         | 2.9 ± 0.5            | 2.2 ± 0.4                 | 2.1 ± 0.3             | 0.05  |

Data are expressed as mean ± standard deviation or as frequencies (percentages)

Abbreviations. BMI Body Mass Index, NF-κB nuclear factor kappa B, NS not significant, Romo1 reactive oxygen specific modulator 1, SFRP4 secreted frizzled-related protein 4, TFF3 trefoil factor 3
As shown in Fig. 2, serum levels of Romo-1 and TFF3 were 1.8 and 2.682 ng/mL, respectively, while sensitivity and specificity for discriminating OC from the control group were, respectively, 67.5% and 60% for Romo-1, 62.5% and 60% for TFF3. All serum markers levels according to the EC, OC and control group are reported in Fig. 3.

All the other markers have sensitivity and specificity values below 60%. Therefore, the most sensitive and specific markers were Romo-1 and TFF3.

For more details about TFF3, Romo1, NF-κB and SFRP4 serum levels, sensitivity and specificity, see Figs. 1 and 2.

Patients with EC were separately analyzed (Table 2). Twenty-eight patients had an endometrioid EC, whereas three non-endometrioid (serous) EC. None of the serum biomarkers differed significantly between endometrioid and non-endometrioid EC. Eleven and 13 of 31 patients had stage IA and IB diseases, respectively. One patient had stage IIIA, and six patients had stage IIIC disease. Mean serum TFF-3 and NF-κB levels were significantly higher in advanced stages. In addition, increased serum levels of TFF3 and NF-κB were found in those with a higher grade of the disease. Only one patient had recurrence within a median follow-up time of 24 months (range 15–40).

Table 3 shows the separate analysis of OC patients. The pathological subtypes of malignant ovarian tumors included serous cystadenocarcinoma (33), mucinous adenocarcinoma (3), endometrioid adenocarcinoma (3) and clear cell carcinoma (1). None of the serum biomarkers differed significantly among histological subtypes. Among OC patients, 85% had stage III and IV. Significantly increased serum levels of NF-κB were observed in patients with advanced-stage compared to those with stage I and II diseases. Three, 9 and 28 patients had grade (G) 1, 2 and 3 diseases, respectively. Higher serum levels of TFF3 and NF-κB were associated with the higher grade. Complete cytoreduction was achieved in 33 of 40 patients and was found to be correlated with lower NF-κB levels. The overall recurrence rate was 10% within a median follow-up time of 19 months (range 15–33 months). No difference in serum biomarker levels was found between those who had a recurrence and those who had not.

Discussion

To date, the use of molecular biomarkers in cancer research has made possible the identification of novel oncogenes/tumor suppressor genes that might be implicated in the development and progression of cancer, and that can be used as tumor biomarkers [24, 25]. Indeed, the panorama of oncological therapies in recent years has been revolutionized...
Table 2 Clinical characteristics and serum TFF3, Romo1, NF-κB and SFRP4 levels of patients with endometrial cancer

| Histology       | n (%) | TFF3, ng/mL p | Romo1, ng/mL p | NF-κB, ng/mL p | SFRP4, ng/mL p |
|-----------------|-------|---------------|----------------|----------------|---------------|
| Endometrioid    | 28 (90.3) | 3.671 ± 0.211 | 2.6 ± 0.2      | 3.2 ± 0.4      | 2.3 ± 0.5      |
| Non-endometriod | 3 (9.7)  | 3.692 ± 0.42   | 2.6 ± 0.3      | 3.5 ± 0.7      | 2.0 ± 0.1      |

FIGO stage

| FIGO stage | n (%) | TFF3, ng/mL p | Romo1, ng/mL p | NF-κB, ng/mL p | SFRP4, ng/mL p |
|------------|-------|---------------|----------------|----------------|---------------|
| IA         | 11 (35.5) | 3.381 ± 0.309 | 2.3 ± 0.2      | 2.5 ± 0.3      | 2.5 ± 0.2      |
| IB         | 13 (41.9) | 3.619 ± 0.801 | 2.7 ± 0.3      | 2.9 ± 0.5      | 2.1 ± 0.3      |
| II         | 0 –      | –             | –              | –              | –              |
| IIIA       | 1 (3.2)  | 3.68          | 2.7            | 3.8            | 2.2            |
| IIIB       | 0 –      | –             | –              | –              | –              |
| IIIC       | 6 (19.4) | 4.418 ± 0.471 | 2.7 ± 0.2      | 3.9 ± 0.4      | 2.2 ± 0.4      |
| IV         | 0 –      | –             | –              | –              | –              |

Histologic grade

| Histologic grade | n (%) | TFF3, ng/mL p | Romo1, ng/mL p | NF-κB, ng/mL p | SFRP4, ng/mL p |
|------------------|-------|---------------|----------------|----------------|---------------|
| 1                | 8 (25.8) | 3.32 ± 0.23   | 2.4 ± 0.3      | 2.5 ± 0.3      | 2.4 ± 0.3      |
| 2                | 17 (54.8) | 3.618 ± 0.35  | 2.7 ± 0.3      | 2.9 ± 0.5      | 2.3 ± 0.5      |
| 3                | 6 (19.4) | 4.333 ± 0.36  | 2.7 ± 0.3      | 3.9 ± 0.4      | 2.0 ± 0.1      |

Recurrence

| Recurrence | n (%) | TFF3, ng/mL p | Romo1, ng/mL p | NF-κB, ng/mL p | SFRP4, ng/mL p |
|------------|-------|---------------|----------------|----------------|---------------|
| No         | 30 (96.8) | 3.672 ± 0.245 | 2.6 ± 0.2      | 3.2 ± 0.4      | 2.2 ± 0.4      |
| Yes        | 1 (3.2)  | 4.301         | 2.7            | 3.1            | 1.7            |

Data are expressed as mean ± standard deviation or as frequencies (percentages)

Abbreviations: NF-κB nuclear factor kappa B, NS not significant, Romo1 reactive oxygen specific modulator 1, SFRP4 secreted frizzled-related protein 4, TFF3 trefoil factor 3

Table 3 Clinical characteristics and serum TFF3, Romo1, NF-κB and SFRP4 levels of patients with ovarian cancer

| Histology       | n (%) | TFF3, ng/mL p | Romo1, ng/mL p | NF-κB, ng/mL p | SFRP4, ng/mL p |
|-----------------|-------|---------------|----------------|----------------|---------------|
| Serous          | 33 (82.5) | 3.708 ± 0.17  | 2.6 ± 0.3      | 3.4 ± 0.4      | 2.0 ± 0.4      |
| Mucinous        | 3 (7.5)  | 3.662 ± 0.92  | 2.2 ± 0.2      | 2.5 ± 0.1      | 2.8 ± 0.3      |
| Endometrioid    | 3 (7.5)  | 3.671 ± 0.1   | 2.5 ± 0.2      | 3.1 ± 0.1      | 2.4 ± 0.4      |
| Clear cell      | 1 (2.5)  | 3.652         | 2.6            | 2.8            | 2.2            |

FIGO Stage

| FIGO Stage | n (%) | TFF3, ng/mL p | Romo1, ng/mL p | NF-κB, ng/mL p | SFRP4, ng/mL p |
|------------|-------|---------------|----------------|----------------|---------------|
| I          | 4 (10)  | 3.581 ± 0.197 | 2.2 ± 0.2      | 2.3 ± 0.1      | 2.6 ± 0.3      |
| II         | 2 (5)   | 3.672 ± 0.101 | 2.5 ± 0.1      | 2.4 ± 0.1      | 2.6 ± 0.3      |
| III        | 29 (72.5) | 3.710 ± 0.14  | 2.6 ± 0.3      | 3.5 ± 0.4      | 2.1 ± 0.8      |
| IV         | 5 (12.5) | 3.681         | 2.6 ± 0.2      | 3.8 ± 0.2      | 2.2 ± 0.1      |

Histologic grade

| Histologic grade | n (%) | TFF3, ng/mL p | Romo1, ng/mL p | NF-κB, ng/mL p | SFRP4, ng/mL p |
|------------------|-------|---------------|----------------|----------------|---------------|
| 1                | 3 (7.5)  | 3.593 ± 0.97  | 2.3 ± 0.1      | 2.4 ± 0.1      | 2.2 ± 0.3      |
| 2                | 9 (22.5) | 3.612 ± 0.139 | 2.4 ± 0.3      | 2.9 ± 0.3      | 2.1 ± 0.3      |
| 3                | 28 (70)  | 3.711 ± 0.209 | 2.6 ± 0.5      | 3.5 ± 0.4      | 2.1 ± 0.4      |

Residual tumor

| Residual tumor | n (%) | TFF3, ng/mL p | Romo1, ng/mL p | NF-κB, ng/mL p | SFRP4, ng/mL p |
|----------------|-------|---------------|----------------|----------------|---------------|
| 0              | 33 (82.5) | 3.694 ± 0.192 | 2.3 ± 1.0      | 2.8 ± 0.4      | 2.1 ± 0.7      |
| ≤ 1 cm         | 3 (7.5)  | 3.702 ± 0.120 | 2.3 ± 0.3      | 3.3 ± 0.2      | 2.1 ± 0.2      |
| > 1 cm         | 4 (10)   | 3.710 ± 0.913 | 2.5 ± 0.2      | 3.5 ± 0.4      | 2.1 ± 0.2      |

Recurrence

| Recurrence | n (%) | TFF3, ng/mL p | Romo1, ng/mL p | NF-κB, ng/mL p | SFRP4, ng/mL p |
|------------|-------|---------------|----------------|----------------|---------------|
| No         | 36 (90) | 3.695 ± 0.223 | 2.1 ± 0.3      | 3.0 ± 0.9      | 2.1 ± 0.4      |
| Yes        | 4 (10)  | 3.708 ± 0.101 | 2.1 ± 0.1      | 3.6 ± 0.3      | 2.1 ± 0.1      |

Data are expressed as mean ± standard deviation or as frequencies (percentages)

Abbreviations: NF-κB nuclear factor kappa B, NS not significant, Romo1 reactive oxygen specific modulator 1, SFRP4 secreted frizzled-related protein 4, TFF3 trefoil factor 3
by the molecular study of cancer, which has allowed new therapeutic strategies, the so-called targeted therapy, and immunotherapy. In this respect, Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), initially used only for OC patients with mutations in BRCA1/2, are the most representative example of targeted therapy [26]. In the BRCA mutation carriers, the role of CA125 evaluation has been described in two different settings by Grandi et al.: in the first one, the need for an integrated clinical work-up including CA125 dosage, ultrasound and computed tomography (CT) examination for the early detection of OC [7]; in the second one, in BRCA 1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy, where CA125 level reduction has been found only partially associated with surgery [8]. However, few markers are currently available and used in endometrial and ovarian cancer [27, 28]. Over the years different risk factors have been associated with the development of EC rather than OC, such as hormonal therapy, smoke, obesity, the latter always associated with EC: a recent study has confirmed how an increase in BMI is associated with endometrial rather than ovarian cancer, but both serous and endometrioid histotypes [29]. Although CA125 is commonly used in the clinic for these reasons, it is endowed with low sensitivity and specificity [30, 31]. Nevertheless, it still represents a useful serum marker to early differentiate between OCs and BOTs with higher sensitivity for stage I endometrioid OC compared to other OC histotypes [32].

Thus, in the last years, several researchers tried to define new molecules that can be helpful in the diagnosis and or prognosis of these tumors. Identifying new prognostic factors besides new therapeutic approaches may help distinguish different biological subgroups. This is particularly important for patients who develop recurrent disease in gynecological neoplasms and associated with poor prognosis. TFF3 alterations have been demonstrated also in gynecological cancers, such as endometrial and ovarian tumors [17, 40]. In light of this, TFF3 may play a role in regulating cancer progression by increasing tumor metastasis by promoting anti-apoptosis, pro-invasive and angiogenesis agents [41]. In a study by Bignotti et al., a significantly higher serum TFF3 level in endometrioid EC patients when compared with healthy women or patients with endometrial hyperplasia was found [36]. Moreover, serum TFF3 levels showed higher sensitivity in the detection of patients with G3-endometrioid EC when compared with CA125 levels. This evidence may support the design of prospective studies evaluating the potential of TFF3 as a new tool for pre- and post-operative surveillance of EC patients. In our study, increased serum levels of TFF3 were found in patients with a higher grade of the disease both in EC and OC.

In a more recent study, Neubert et al. analyzed TFF3 levels in 89 women who underwent hysterectomy and endometrial biopsy for postmenopausal bleeding [42–45], showing how TFF3 levels were significantly higher in patients with endometrial carcinoma compared with endometrial hyperplasia group [46]. Pandey et al., in a study conducted to evaluate the role of tamoxifen in the EC, observed that elevated TFF3 protein expression was found in EC but not in normal endometrial tissue, and its elevated expression in EC cells increased oncogenicity, invasiveness and tumor growth, as well as myometrial invasion. Moreover, it explained how tamoxifen’s implication in overexpression of TFF3 in EC cells was critical in promoting EC progression [47]. As regards these data, prospects can be focused on evaluating of inhibition of TFF3 function to limit the progression of EC. El-Balat et al. analyzed the expression of TFF3 in a cohort of 137 borderline tumors of the ovary (BOT): none of the serous and endometrioid BOT showed strong TFF3 expression. On the contrary, a higher TFF3 expression was found in BOT mucinous histology and BOT with mixed histology, suggesting a potential function of the protein in these histological subtypes [37]. Expression analysis of TFF3 was performed in a cohort of 91 OC patients by Hoellen et al. No significant difference in TFF3 expression was found based on age, FIGO stage or residual tumor; meanwhile, a significant correlation of TFF3 expression and grade was detected [48]. However, since few studies have been carried out on
TFF3 expression and its role in EC and OC and, mostly, few studies have considered its prognostic value, TFF3 expression deserves further investigation.

The idea of analyzing the expression of Romo1 in EC and OC comes from the evidence of its role in the process of invasion and also the progression of cancer cells [35, 48]. It is involved in normal cellular processes, such as cell proliferation, senescence, and death. As ROS regulating protein, Romo1 is associated with the level of oxidative stress and the production of ROS in cancerous cells, considering that one of the most important causes for the incidence of cancer is the increase of free radicals and ROS [49]. Moreover, oxidative stress-induced Romo-1 expression is associated with tumor cell invasion via NF-κB signaling has been reported to increase constitutive activation of NF-κB in hepatocellular carcinoma [50]. Therefore, oxidative stress, promote tumor cell invasion through Romo-1 expression and constitutive NF-κB activation. For these reasons, it is reasonable to assume Romo-1 as a promising therapeutic target for diseases characterized by NF-κB deregulation. The evidence in our study of Romo-1 overexpression in OC and EC makes this molecule susceptible to more detailed and wider research.

Further evidence about the role of NF-κB, as a key link between inflammation and cancer, and its increased activity has been reported in several types of cancer. The activation of NF-κB signaling can occur through canonical or non-canonical pathways which have distinct roles in tumor progression; moreover, cancer cells have been shown to produce different proinflammatory and proangiogenic substances in direct response to NF-κB activity, as found in OC [51]. Indeed, in OC, the deregulated NF-κB activity promotes chemoresistance, cancer stem cell maintenance, metastasis and immune evasion. Although NF-κB is an attractive target in OC, current therapeutic strategies are limited due to unwanted side effects, caused by wide inhibition of this major signaling pathway in normal physiological and immunological cellular functions. For these reasons, next research may be enforced to suppress NF-κB only in the tumor cell population of OC and concurrently activate canonical NF-κB signaling in immune cells to promote and support anti-tumor immunity.

Finally, the finding of altered expression in serum level of SFRP4 evaluated in our study, resulting in a lower serum SFRP4 expression in cancer groups compared to the control one, seems to agree with recent literature data [52]. SFRP4 is a putative modulator of the Wnt signaling pathway, important in cell proliferation, and may be implicated as a tumor suppressor: indeed, under normal conditions, SFRP4 can function as a suppressor of cell growth and variations in the expression level of SFRP4 has been found in many tumors, such as endometrial, cervical, ovarian, prostate, bladder, colorectal, mesothelioma, pancreatic, renal, and oesophageal tumors [53, 54]. In a study conducted by Pohl et al., it has been found that SFRP4 expression is decreased in the normal endometrium when compared to EC cells and from the analysis made in serous OC cells, SFRP4 protein expression is decreased, predicting a poorer outcome and prognosis [38, 53, 55].

**Strengths and limitations**

A limitation of our study is represented by the small number of patients analyzed and the heterogeneity of the population sample (regarding age, tumor histotype and stage of the disease).

Despite the aforementioned limitations, there are several strengths of our study: the presence of a control group and its prospective design.

**Conclusions**

Nowadays, non-invasive methods for diagnosis and prognosis of EC and OC are needed and there is growing interest in the evaluation of the role of specific serum biomarkers. Up to date, many studies try to define are the best molecules to analyze, preferring those with high sensitivity and specificity. The CA125 assay remains a useful, low-cost and easy tool for the initial and follow-up evaluation of OC patients as well as the assessment of BRCA mutation carriers in patients with high risk or initial diagnosis of OC. This paper tries to play a role in this scenario, evaluating serum TFF3, Romo-1, NF-κB and SFRP4 concentrations to determine their levels in the EC and OC patients: in our case, the patients with EC and OC had TFF3, Romo-1 and NF-κB serum levels significantly higher and SFRP4 serum levels lower compared to the control one. Their sensibility and specificity for discriminating EC and OC compared to the control group show encouraging values, although no one reaches 70%. Future prospective and randomized trials are needed to define new biomarkers which could also help to identify specific markers for molecular targets therapy [26].

**Author contributions** HT, SGV, and IK: protocol development, data management and analysis, and manuscript writing. AA and SD: data collection and analysis and manuscript writing. LDC, PG, VS, NT, TB, MA, and FD: manuscript writing. RG and SI: manuscript revisiting. HU: manuscript revising and supervision.

**Funding** The study was evaluated, selected and funded [funding number: TAB-2017–22506] by Istanbul University-Cerrahpasa, School of Medicine, Turkey, after rigorous peer-review.
Declarations

Conflict of interest The authors declare that they have no conflicts of interest to disclose regarding this publication.

Research involving human participants and/or animals All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of Istanbul University-Cerrahpasa, School of Medicine (registration number: 83045809-604.01.02).

Consent to participate Informed consent was obtained from all individual participants included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD et al (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68(4):284–296
2. Cancer Research UK. Cancer Research UK Uterine Cancer Statistics 2014 [Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer/incidence#heading-One]
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
4. Della Corte L, Giampaolino P, Mercorio A, Riemer D, Winer N et al (2021) Endometrial cancer: a systematic review of HE4, REM and REM-B. Clin Chim Acta 515:27–36
5. Samson MH, Chaiyarat P, Nortvig H, Vestergaard EM, Ernst E, Nexo E (2011) TFF3 factor family peptides in human saliva and cervical mucus. Method evaluation and results on healthy individuals. Clin Chem Lab Med 49(5):861–868
6. Thim L, May FE (2005) Structure of mammalian trefoil factors and functional insights. Cell Mol Life Sci 62(24):2956–2973
7. Xiao P, Ling H, Lan G, Liu J, Hu H, Yang R (2015) TFF3 factors: gastrointestinal-specific proteins associated with gastric cancer. Clin Chim Acta 450:127–134
8. Thim L, May FE, Westley BR (2015) TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer. Endocr Relat Cancer 22(3):465–479
9. Mhawech-Fauceglia P, Wang D, Samrao D, Liu S, DuPont NC, Pejovic T (2013) TFF3 factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma. Gynecol Oncol 130(1):174–180
10. Dolcet X, Llobet D, Pallares J, Matias-Guiu X (2005) NF-kB in development and progression of human cervix. Virchows Arch 446(5):475–482
11. Chung JS, Park S, Park SH, Park ER, Cha PH, Kim BY et al (2012) Overexpression of Romo1 promotes production of reactive oxygen species and invasiveness of hepatic tumor cells. Gastroenterology 143(4):1084–1094 (e7)
12. Jo MJ, Kim BG, Park SH, Kim HJ, Jeong S, Kim BR et al (2020) Romo1 inhibition induces TRAIL-mediated apoptosis in colorectal cancer. Cancers (Basel) 12(12):2358
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP et al (2014) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12(12):1495–1499
14. Amant F, Mirza MR, Koskas M, Creutzberg CL (2018) Cancer of the corpus uteri. Int J Gynaecol Obstet 143(Supp1):37–50
15. Berek JS, Kehoe ST, Kumar L, Friedlander M (2018) Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 143(Suppl 2):39–78
16. Hristova VA, Chan DW (2019) Cancer biomarker discovery and translation: proteomics and beyond. Expert Rev Proteomics 16(2):93–103
17. Gurel C, Inetas G, Hortu I, Tunc E, Kuscu GC, Dindaroglu FC et al (2019) Cancer and cancer stem cells: new molecular perspectives. Crit Rev Oncog 24(1):99–104. https://doi.org/10.1615/CritRevOncog.2019029628
18. Della Corte L, Foreste V, Di Filippo C, Giampaolino P, Bifulco G (2021) Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know. Expert Opin Investig Drugs 30(5):543–554. https://doi.org/10.1080/13543784.2021.1901882 (Epub 2021 Mar 24)
27. Bonifacio VDB (2020) Ovarian cancer biomarkers: moving forward in early detection. Adv Exp Med Biol 1219:355–363
28. Umelo IA, Costanza B, Castronovo V (2018) Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies. Cancer Metastasis Rev 37(1):125–145
29. Grandi G, Perrone AM, Chiassi G, Friso S, Toss A, Sammarini M et al (2019) Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study. Gynecol Oncol 154(1):163–168. https://doi.org/10.1016/j.ygyno.2019.04.684 (Epub 2019 May 16)
30. Funston G, Hamilton W, Abel G, Crobbie EJ, Rous B, Walter FM (2020) The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: a population-based cohort study. PLoS Med 17(10):e1003295
31. Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH (2005) Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 50(8):585–590
32. Grandi G, Perrone AM, Toss A, Vitigliano A, Friso S, Facchinetti F et al (2020) The generally low sensitivity of CA 125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype. Minerva Med 111(2):133–140. https://doi.org/10.23736/S0026-4806.20.06474-5
33. Borozan I, Wilson S, Blanchette P, Laflamme P, Watt SN, Krzyzanoski PM et al (2012) CaPSID: a bioinformatics platform for computational pathogen sequence identification in human genomes and transcriptomes. BMC Bioinform 13:206
34. Mitra S, Das S, Chakrabarti J (2013) Systems biology of cancer biomarker development. Cancer Biomark 13(4):201–213
35. Amini MA, Talebi SS, Karimi J (2019) Reactive Oxygen Species Modulator 1 (ROM1), a new potential target for cancer diagnosis and treatment. Chonnam Med J 55(3):136–143
36. Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M et al (2008) Trefoil factor 3, a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer 99(5):768–773
37. El-Balat A, Schmeil I, Karn T, Holtrich U, El-Balat A, Otto M et al (2016) Trefoil factor 3 expression as stratification marker in borderline ovarian cancer patients. Ceska Gynekol 83(2):109–114
38. Pandey V, Zhang M, Chong QY, You M, Raquib AR, Pandey AK et al (2017) Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells. Oncotarget 8(44):77268–77291
39. Neubert D, Ondrova D, Hamblet J, Maderka M, Sobkova K, Stejskal D et al (2018) Elevated levels of TFF3 in endometrial cancer patients. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
40. Vitale SG, Caruso S, Garzon S, Vecchio GM, La Rosa VL et al (2021) Comparison of three biopsy forceps for hysteroscopic endometrial biopsy in postmenopausal patients (HYGREG-1): a multicenter, single-blind randomized clinical trial. Int J Gynaecol Obstet 155(3):425–432
41. Vitale SG (2020) The biopsy snake grasper sec. VITALE: a new tool for office hysteroscopy. J Minim Invasive Gynecol 27(6):1414–1416
42. Vitale SG, Riemma G, Ciebiera M, Cianci S (2020) Hysteroscopic treatment of submucosal fibroids in perimenopausal women: when, why, and how? Climacteric 23(4):355–359
43. Vitale SG, Haimovich S, Riemma G, Ludwin A, Zizolfi B, De Angelis MC et al (2020) Innovations in hysteroscopic surgery: expanding the meaning of “in-office.” Minim Invasive Ther Allied Technol 30(3):125–132
44. Neubert D, Ondrova D, Maderka M, Sobkova K, Stejskal D et al (2018) Elevated levels of TFF3 in endometrial cancer patients. Ceska Gynekol 83(2):109–114
45. Pandey V, Zhang M, Chong QY, You M, Raquib AR, Pandey AK et al (2017) Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells. Oncotarget 8(44):77268–77291
46. Neubert D, Ondrova D, Hamblet J, Maderka M, Sobkova K, Stejskal D et al (2018) Elevated levels of TFF3 in endometrial cancer patients. Ceska Gynekol 83(2):109–114
47. Pandey V, Zhang M, Chong QY, You M, Raquib AR, Pandey AK et al (2017) Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells. Oncotarget 8(44):77268–77291
48. Hoellen F, Kostara A, Karn T, Holtrich U, El-Balat A, Otto M et al (2016) Trefoil factor 3 expression in epithelial ovarian cancer exerts a minor effect on clinicopathological parameters. Mol Clin Oncol 5(4):422–428
49. Klaunig JE (2018) Oxidative stress and cancer. Curr Pharm Des 24(40):4771–4778
50. Lee S, Park YH, Chung JS, Yoo YD (2015) Romo1 and the NF-kappaB pathway are involved in oxidative stress-induced tumor cell invasion. Int J Oncol 46(5):2021–2028
51. Li H, Ye X, Mahanivong C, Bian D, Chan J, Huang S (2005) Signaling mechanisms responsible for lysosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. J Biol Chem 280(11):10564–10571
52. Hrzenjak A, Tippm M, Kremser ML, Stroehmeier B, Guclly C, Neumeister D et al (2004) Inverse correlation of secreted frizzled-related protein 4 and beta-catenin expression in endometrial stromal sarcomas. J Pathol 204(1):19–27
53. Carmon KS, Loose DS (2008) Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells. Mol Cancer Res 6(6):1017–1028
54. Drake J, Shearwood AM, White J, Friis R, Zeps N, Charles A et al (2009) Expression of secreted frizzled-related protein 4 (SFRP4) in primary serous ovarian tumours. Eur J Gynaecol Oncol 30(2):133–141
55. Jacob F, Ukegjini K, Nixdorf S, Ford CE, Olivier J, Caduff R et al (2012) Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients. PLoS ONE 7(2):e31885

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Hasan Turan1 · Salvatore Giovanni Vitale2 · Ilker Kahramanoglu3 · Luigi Della Corte4 · Pierluigi Giampaolino5 · Asli Azemi6 · Sinem Durmus6 · Veyssel Sal7 · Nedim Tokgozoglu8 · Tugan Bese9 · Macit Arvas10 · Fuat Demirkiran9 · Remise Gelisgen6 · Sennur Ilvan11 · Hafize Uzun6
1 Department of Gynecologic Oncology, Health Science University, Cam Sakura Training and Research Hospital, Istanbul, Turkey
2 Obstetrics and Gynecology Unit, Department of General Surgery and Medical Surgical Specialties, University of Catania, Via Santa Sofia 78, 95123 Catania, Italy

2113Archives of Gynecology and Obstetrics (2022) 306:2105–2114
3 Department of Gynecologic Oncology, Emsey Hospital, Istanbul, Turkey
4 Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples, Naples, Italy
5 Department of Public Health, University of Naples Federico II, Via Sergio Pansini, Naples, Italy
6 Department of Biochemistry, School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
7 Department of Obstetrics and Gynecology, Memorial Bahcelievler Hospital, Istanbul, Turkey
8 Department of Gynecologic Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey
9 Department of Gynecologic Oncology, School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
10 Department of Gynecologic Oncology, American Hospital, Istanbul, Turkey
11 Department of Pathology, School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey